Moleculin Shares Dip Despite Positive Trial Results

Moleculin Biotech shares are trading lower despite announcing positive results from a Phase 1 clinical trial of WP1066 for pediatric recurrent malignant brain tumors, indicating potential investor concerns over financial constraints for future trials.